Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Lava Therapeutics N.V. (LVTX)

Lava Therapeutics N.V. (LVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,543
  • Shares Outstanding, K 25,350
  • Annual Sales, $ 6,770 K
  • Annual Income, $ -41,970 K
  • 60-Month Beta 0.64
  • Price/Sales 10.82
  • Price/Cash Flow N/A
  • Price/Book 0.80
Trade LVTX with:

Options Overview Details

View History
  • Implied Volatility 133.47% ( -18.40%)
  • Historical Volatility 109.62%
  • IV Percentile 21%
  • IV Rank 8.46%
  • IV High 1,355.02% on 09/13/23
  • IV Low 20.63% on 08/14/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 62
  • Volume Avg (30-Day) 104
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 1,369
  • Open Int (30-Day) 1,666

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.25
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.41
  • Prior Year -0.53
  • Growth Rate Est. (year over year) +52.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.51 +9.16%
on 04/10/24
4.21 -34.92%
on 03/27/24
-0.91 (-24.93%)
since 03/22/24
3-Month
1.58 +73.42%
on 01/31/24
6.47 -57.65%
on 02/29/24
+1.18 (+75.64%)
since 01/24/24
52-Week
1.13 +142.26%
on 10/30/23
6.47 -57.65%
on 02/29/24
+1.14 (+71.25%)
since 04/24/23

Most Recent Stories

More News
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END

OCEA : 1.4150 (-4.39%)
ONCY : 1.0600 (unch)
ONC.TO : 1.47 (+2.80%)
LVTX : 2.74 (-8.05%)
MRK : 127.00 (+0.09%)
ABBV : 167.80 (-1.03%)
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

ONCY : 1.0600 (unch)
ONC.TO : 1.47 (+2.80%)
LVTX : 2.74 (-8.05%)
MRK : 127.00 (+0.09%)
ABBV : 167.80 (-1.03%)
Geron (GERN) Reports Q1 Loss, Misses Revenue Estimates

Geron (GERN) delivered earnings and revenue surprises of 22.22% and 85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

GERN : 3.58 (+2.29%)
LVTX : 2.74 (-8.05%)
Selecta Biosciences, Inc. (SELB) Reports Q1 Loss, Misses Revenue Estimates

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -37.50% and 59.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

SELB : 0.8812 (-8.00%)
LVTX : 2.74 (-8.05%)
ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 35.71% and 30.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

ITOS : 10.57 (-3.82%)
LVTX : 2.74 (-8.05%)
Curis (CRIS) Reports Q4 Loss, Misses Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of 14.29% and 4.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CRIS : 14.77 (-1.60%)
LVTX : 2.74 (-8.05%)
Can LAVA Therapeutics N.V. (LVTX) Climb 198% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for LAVA Therapeutics N.V. (LVTX) points to a 197.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

LVTX : 2.74 (-8.05%)
LAVA Therapeutics N.V. (LVTX) Q3 Earnings Surpass Estimates

LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 157.14% and 38.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

LVTX : 2.74 (-8.05%)
CDMO : 6.83 (+2.25%)
Will LAVA Therapeutics N.V. (LVTX) Report Negative Q3 Earnings? What You Should Know

LAVA Therapeutics N.V. (LVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LVTX : 2.74 (-8.05%)
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of 1.15% and 131.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

VRDN : 13.03 (-8.56%)
LVTX : 2.74 (-8.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

LAVA Therapeutics B.V. is a biotechnology company. It focuses on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy. LAVA Therapeutics B.V. is based in UTRECHT, The Netherlands.

See More

Key Turning Points

3rd Resistance Point 3.20
2nd Resistance Point 3.11
1st Resistance Point 2.92
Last Price 2.74
1st Support Level 2.64
2nd Support Level 2.55
3rd Support Level 2.36

See More

52-Week High 6.47
Fibonacci 61.8% 4.43
Fibonacci 50% 3.80
Fibonacci 38.2% 3.17
Last Price 2.74
52-Week Low 1.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar